Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1 to 2 of 2 results for cangrelor

  1. Coronary revascularisation: Cangrelor (ESNM63)

    Summary of the evidence on cangrelor for coronary revascularisation to inform local NHS planning and decision-making

    Evidence summary
    Published
    3 November 2015

  2. Cangrelor for reducing atherothrombotic events in people undergoing percutaneous coronary intervention or awaiting surgery requiring interruption of anti‑platelet therapy (terminated appraisal) (TA351)

    NICE is unable to make a recommendation about the use in the NHS of cangrelor for reducing atherothrombotic events in people undergoing percutaneous coronary intervention or awaiting surgery requiring interruption of anti-platelet therapy because no evidence submission was received from The Medicines Company.

    Technology appraisal guidance
    Published
    22 July 2015

    Sections for TA351